Struthers Richard Scott 4
4 · Crinetics Pharmaceuticals, Inc. · Filed May 10, 2024
Insider Transaction Report
Form 4
Struthers Richard Scott
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2024-05-08$9.28/sh+107,448$997,117→ 364,933 total - Sale
Common Stock
2024-05-08$49.40/sh−107,448$5,307,931→ 257,485 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-08−107,448→ 16,342 totalExercise: $9.28Exp: 2028-05-24→ Common Stock (107,448 underlying)
Holdings
- 570,805(indirect: By Trust)
Common Stock
- 110,000(indirect: By Trust)
Common Stock
- 110,000(indirect: By Trust)
Common Stock
- 110,000(indirect: By Trust)
Common Stock
- 1,000(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023.
- [F2]The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.40 per share. The range of sales prices on the transaction date was $48.95 to $50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.